NCT01018758View on ClinicalTrials.gov

Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

July 31, 2006

Study Completion Date

July 31, 2008

Conditions
Chemotherapy-Induced Nausea and VomitingNon Hodgkin's Lymphoma
Interventions
DRUG

Palonosetron

Palonosetron will be given as an intravenous bolus at the dose of 250 micrograms over 30 seconds beginning 30 minutes before chemotherapy.

Trial Locations (1)

41100

Gruppo Italiano Studio Linfomi, Modena

All Listed Sponsors
lead

Gruppo Italiano Studio Linfomi

OTHER

NCT01018758 - Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy | Biotech Hunter | Biotech Hunter